Abstract: In a threaded joint for pipes constituted by a pin and a box, each having a contact surface comprising a threaded portion and an unthreaded metal contact portion, the contact surface of the pin has a solid corrosion protective, preferably transparent coating based on a UV-curable resin and the contact surface of the box has a solid lubricating coating having plastic or viscoplastic rheological behavior which is preferably formed by the hot melt technique from a composition comprising a thermoplastic polymer, a wax, a metal soap, a corrosion inhibitor, a water-insoluble liquid resin, and a solid lubricant.

Abstract: Processes and systems are provided for effectively degumming vegetable oils with the use of an acid and base pretreated mixture of vegetable oil. The pretreated mixture is subjected to compression and one or more intervals of explosive decompression of the compressed mixture to form a degummed vegetable oil. Also provided are compression and decompression rates and conditions that can be used to effectively degum vegetable oil to achieve reduced levels of phosphorus and metals such as iron, calcium and magnesium.

Abstract: According to the present invention there is provided a method of processing rice oil comprising the steps of removing one or more phosphorus compounds from the rice oil; heating the rice oil to a temperature of between 200° C.-260° C.; applying a pressure of between 0.1-1 kgf/cm2 to the rice oil; extracting a by-product from the rice oil.

Abstract: Laundry detergents useful for cold-water cleaning and boosted bargain detergents are disclosed. The detergents include a surfactant composition derived from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives. For fatty alkyl ester sulfonate-containing detergents, the composition is selected from C10 betaines, C12 or C16 amidoamines, C12 ethanolamine amides, C16 amidoamine sulfonates, C18 diamidoamine dioxides, quaternized C18 diamidoamine betaines, sulfonated C18 low-EO fatty ester alkoxylates, C18 amidoamine carboxylates, and amidoamine oxides and sulfobetaines derived from cross-metathesis of palm or soybean oil. The bargain detergents include a performance booster selected from C12 low-EO fatty ester alkoxylate sulfonates, C18 amidoamine oxide esters, C18 amidoamine oxide carboxylates, and amidoamine sulfobetaines made from self metathesized palm or soybean oil.

Abstract: The invention relates to combinations of 1-aza-3,7-dioxabicyclo[3.3.0]octane compounds with silicic acid esters, methods for producing same, the use of same as pro-fragrances, as well as washing and cleaning agents, fabric softeners and cosmetics that contain same. The invention also relates to a method for prolonging the perception of fragrance in such agents.

Abstract: The invention provides improved deposition and reduced leakage benefits from a particle comprising: (a) a core comprising a benefit agent; (b) a shell, wherein the shell comprises a crosslinked, hydrophobically modified polyvinyl alcohol, which comprises a crosslinking agent comprising i) a first dextran aldehyde having a molecular weight of from 2,000 to 50,000 Da; and ii) a second dextran aldehyde having a molecular weight of from greater than 50,000 to 2,000,000 Da.

Abstract: An apparatus and method is described for culturing and conditioning cells on a sample. The apparatus includes a fluid delivery system that transmits gas to a first surface of a sample and transmits liquid to an opposite surface of the sample without transmitting liquid onto the first surface. Further, while culturing cells on the sample, the apparatus enables a constant or variable tension and shear stress applied to the sample. The apparatus may thus, for example, be used to culture cells on an external surface of a tissue construct with air and culture cells underneath the tissue construct with a cell growth media. The fluid delivery system may alternatively transmit liquid cell growth media underneath and on the sides of the tissue construct without flowing onto a designated external surface of the tissue construct.

Abstract: A filter device is provided which includes a well, at least one top access opening to the well, and a horizontally-disposed filter. The well, which includes an inner surface at least partially defining the well, also includes a first well chamber to accommodate a fluid and a second well chamber to accommodate a fluid. The first well chamber and the second well chamber are separate chambers, and the inner surface at least partially defines the first well chamber and at least partially defines the second well chamber. The at least one top access opening provides independent top access to the first well chamber and the second well chamber, and the horizontally-disposed filter is positioned between and at least partially separates the separate first well chamber and second well chamber of the well.

Abstract: This invention relates to optomechanical systems and methods for altering, modifying or disrupting a target object. Such systems and methods are used for, for example, ablating the endogenous nucleus in a cell.

Abstract: Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood into a plasma component containing proteins, a platelet component and a buffy coat component. A plastic treatment device is provided having plastic channels that allow transmittance of light to the interior of the plastic device and a light source that produces light of a wave length selected to activate the photoactivatable agent. The plasma component containing proteins is first pumped through the plastic treatment device, followed by the platelet component and finally the buffy coat component. The resulting treated cells may be incubated or reinfused directly to the subject.

Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.

Abstract: The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects.

Abstract: Novel MSC stem-cell culture and therapy methods and culture medium compositions for the purpose of inducing, activating, or priming discrete uniform cell phenotypes to selectively promote or suppress inflammation and immunity, yielding polarized, primed, activated, or induced cells used in cell-based therapy.

Abstract: The present invention discloses a stem cell culture medium and its applications as well as a stem cell culture method. The said stem cell culture medium contains no serum. The said stem cell culture medium contains amino acids, vitamins, salts, lipids, cytokines and protein polypeptides. The said stem cell culture medium is suitable for rapid culture of stem cells derived from human and mammalian tissues, including but not limited to, adipose mesenchymal stem cells, bone marrow mesenchymal stem cells and umbilical cord blood stem cells. The said culture medium can increase the proliferation speed of the stem cells 3-5 times, without any affects on their differentiation potentials. Comparing the said stem cell culture medium to a routine culture medium, the said culture medium is not only able to proliferate stem cells derived from different sources more rapidly and achieve more proliferation generations, but also keep their differentiation potentials well.

Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.

Abstract: Provided are embryonic stem (ES) cell-derived tissue modeling systems. In particular, systems for the de novo generation of tissue by parallel drug selection of cell types constituting the tissue of interest in one culture of differentiating ES cells is described as well as the use of such systems in transplantation and drug development.

Abstract: A method for producing a regenerative hair follicle germ for transplantation, in which a color of hair that grows after transplantation is controlled, includes preparing a first cell mass containing mesenchymal cells; preparing a second cell mass containing epithelial cells; preparing a cell mass containing pigment stem cells; binding the cell mass containing the pigment stem cells to at least one among the first cell mass and the second cell mass, and closely contacting the first cell mass and the second cell mass, at least one of which has been bound to the cell mass containing the pigment stem cells, and culturing them within a support.

Abstract: This disclosure provides peptides, polypeptides, fusion polypeptides, compositions, and methods for enhancing or increasing the stability of a polypeptide (e.g., Taq polymerase). Such peptides, polypeptides, fusion polypeptides, or compositions include polypeptides linked to a peptide tag that enhances the stability of the polypeptide. The peptides, polypeptides, fusion polypeptides, compositions may also enhance the activity, specificity, and/or fidelity of other polypeptides in a reaction mixture. The disclosure also provides methods of using such peptides, polypeptides, fusion polypeptides, compositions.

Abstract: The present invention relates to a nucleic acid molecule, which encodes a polypeptide having alcohol dehydrogenase activity, in particular methanol dehydrogenase activity, comprising having a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence as set forth in any one of SEQ ID NOs: 1 (mdh2-MGA3), 3 (mdh3-MGA3), or 5 (mdh2-PB1); (ii) a nucleotide sequence having at least 90% sequence identity, more particularly at least 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity, with a nucleotide sequence as set forth in any one of SEQ ID NOs: 1, 3 or 5; (iii) a nucleotide sequence which is degenerate with any one of the nucleotide sequences of SEQ ID NOs: 1, 3 or 5; (iv) a nucleotide sequence which is a part of the nucleotide sequence of any one of SEQ ID NOs: 1, 3 or 5, or of a nucleotide sequence which is degenerate with a sequence of SEQ ID NOs: 1, 3 or 5; (v) a nucleotide sequence encoding all or part of a polypeptide whose amino acid sequence is set forth in any one of SEQ I

Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.

Abstract: Improved Sso7-polymerase conjugate proteins are provided.

Abstract: The invention relates to a DNA sequence, which codes for a polypeptide having phospholipase activity essentially without lipase activity, characterized in that the DNA sequence is selected from a) DNA sequences that comprise a nucleotide sequence according to SEQ ID NO: 1, b) DNA sequences that comprise the coding sequence according to SEQ ID NO: 1, c) DNA sequences that code for the protein sequence according to SEQ ID NO: 2, d) DNA sequences that are coded for by the plasmid pPL3940-Topo2.5 with the restriction map according to FIG.

Abstract: The present invention relates to a method of producing a fatty acid alkyl ester using microorganisms having the ability to produce oil, and more particularly to a method of producing a fatty acid alkyl ester, the method comprising culturing microorganisms having the ability to produce oil, thus accumulating a large amount of oil in the microorganisms, inducing the autolysis of the produced oil in the microorganisms to produce a free fatty acid, and converting the free fatty acid into an alkyl ester. According to the method of the present invention, oil accumulated in microorganisms, such as triacylglycerol that is typical oil produced by microorganisms, can be converted into a fatty acid alkyl ester with high efficiency using a metabolic engineering approach. Thus, the method of the present invention is useful for the industrial production of a fatty acid alkyl ester which has been recently found to be effective as biodiesel.

Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.

Abstract: Engineered nucleases are promising tools for genome manipulation and determining off-target cleavage sites of these enzymes is of great interest. We developed an in vitro selection method that interrogates 1011 DNA sequences for their ability to be cleaved by nucleases. The method revealed hundreds of thousands of DNA sequences that can be cleaved in vitro by two ZFNs, CCR5-224 and VF2468, which target the endogenous human CCR5 and VEGF-A genes, respectively. Analysis of the identified sites in cultured human cells revealed CCR5-224-induced mutagenesis at nine off-target loci. Similarly, we observed 31 off-target sites cleaved by VF2468 in cultured human cells. Our findings establish an energy compensation model of ZFN specificity in which excess binding energy contributes to off-target ZFN cleavage and suggest strategies for the improvement of future nuclease design. It was also observed that TALENs can achieve cleavage specificity similar to or higher than that observed in ZFNs.

Abstract: The disclosure provides variant Cel6a enzymes having increased thermostability, methods of making and using such polypeptides.

Abstract: The present invention relates to a mutant of L-asparaginase enzyme characterized in having high thermostability, pH stability and no glutaminase activity useful for therapeutics and the process of preparing the same. The present invention specifically relates to mutants MTCC 5580, MTCC 5581 and MTCC 5582 characterized in having higher stability, no glutaminase activity etc., to allow their usage in the form of improved protein therapeutics.

Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

Abstract: This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a CAIX antigenic marker. The novel CAIX variant and related compositions are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, adoptive immunotherapy.

Abstract: There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the passenger domain is essentially intact and the POI(s) is/are fused to the beta stem domain.

Abstract: The present technology provides for enzyme compositions with enhanced enzyme activity, thermophilic and psychrophilic stability.

Abstract: Described herein are methods and systems for harvesting, collecting, separating and/or dewatering algae using iron based salts combined with a magnetic field gradient to separate algae from an aqueous solution.

Abstract: A system for enhancing a nucleic acid sample may include a one pump, a denaturing chamber; a microfluidic hydroxyapatite chromatography device configured for performing hydroxyapatite chromatography on the nucleic acid sample, a sample collector, and tubing connecting the pump with the denaturing chamber, the hydroxyapatite chromatography device and the sample collector such that the pump may be used to move the nucleic acid sample from the denaturing chamber to the hydroxyapatite chromatography device and then to the sample collector.

Abstract: Methods for promoting angiogenesis, and for diagnosing the presence or risk of developing disorders associated with impaired angiogenesis or blood flow to a tissue in the body, using microRNA-26a (miR-26a).

Abstract: Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma.

Abstract: The invention discloses a diagnosis of endometriosis, by determining a level of miR-199a-5p as a biomarker to diagnose endometriosis. The invention also discloses a treatment of endometriosis, by administering pre-miR-199a to a subject in need thereof in a dosage of 4 to 8 mg/per kilogram of body weight per 1 to 3 days for 4 weeks to inhibit the processes of endometriosis development.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.

Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and/or activity, and/or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules, including small nucleic acid molecules such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, that are capable of mediating or that mediate RNA interference (RNAi) against IDH1 or mutant IDH1 gene expression.

Abstract: Disclosed herein are methods for decreasing kallikrein and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

Abstract: Inhibition of DNA2 in Fanconi anemia (FA) cells remedies the over-resection of DNA, thereby stabilizing the FA cells. Inhibition of DNA2 in FA cells allows for safe treatment of cancers in FA patients, a decrease in the lethality of FA cells, a decrease in bone marrow failure of FA patients, and a means for decreasing the incidence of cancer for FA patients.

Abstract: The present invention is directed to a synthetic nucleic acid scaffold comprising one or more subunits, each subunit comprising two or more different protein-binding sequences coupled together. The present invention further relates to systems and methods for assembling a synthetic biological pathway and producing a biological pathway product or a precursor product using the synthetic nucleic acid scaffold.

Abstract: Provided is aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method, and more particularly, a new GO-SELEX method without target immobilization in which a single-stranded nucleic acid pool may react with a non-bound target material or a counter-target material, after which a single-stranded nucleic acid which has not been bound to the target or counter-target may be separated by using the graphene. Also, the specific aptamer obtained through the above-described method may be used for diagnosing target related diseases.

Abstract: The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.

Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.

Abstract: The present invention provides promoters derived from a filamentous fungus. These promoters have application in the fields of molecular biology, microbiology, fungal genetics and production of biofuels and other products.

Abstract: Non-naturally occurring DNA promoters, include MSGT-PFlt, PFlt-UAS-2X and FSgt-PFlt. The MSGT-PFlt was developed and has expression shown to be equivalent to that of CaMV35S promoter. DNA promoters PFlt-UAS-2X and FSgt-PFlt were developed and tested in transient and transgenic system and found to be stronger than the CaMV35S promoter.

Abstract: The present invention relates to genetic constructs, which can be used in the preparation of transgenic plants. The constructs can have the ability of reducing nitrate concentration in the plant, in particular the plant's leaves, and for inducing a senescence-like phenotype. The invention extends to plant cells transformed with such constructs, and to the transgenic plants themselves. The invention also relates to methods of producing transgenic plants, and to methods of reducing nitrate content in plants. The invention also relates to harvested plant leaves, for example tobacco leaves, that have been transformed with the genetic constructs, and to various tobacco articles, such as smoking articles, comprising such harvested plant leaves.

Abstract: The present invention features tobacco nicotine demethylase nucleic acid and amino acid sequences, tobacco plants and plant components containing such sequences, including tobacco plants and plant components having reduced expression or altered enzymatic activity of nicotine demethylase, methods of use of nicotine demethylase sequences to create plants having altered levels of nornicotine or N?-nitrosonornicotine (“NNN”) or both relative to a control plant, as well as tobacco articles having reduced levels of nornicotine or NNN.

Abstract: This invention provides transgenic plant cells with recombinant DNA for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil. Also disclosed are methods for manufacturing transgenic seed and plants with enhanced traits.